A number of alternative treatments for AATD have been proposed, ranging from inhalation therapy to recombinant and transgenic AAT, from gene therapy to regenerative medicine [42-45]: none of these options has so far gone beyond the experimental stage. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.